Skip to main content
Premium Trial:

Request an Annual Quote

Terrapin, Pharmagene Form Research Alliance

Premium

SOUTH SAN FRANCISCO, Calif.--Terrapin Technologies here formed its first alliance with a company that uses bioinformatics when it entered into a collaboration with UK-based Pharmagene late last month to discover therapeutic agents to treat migraine headaches and disorders related to gastrointestinal motility, according to Rey Gomez, Terrapin's vice-president of research and development.

"Our collaboration with Pharmagene is the first of what we expect will be multiple collaborations in the genomics field," stated Clifford Orent, Terrapin's chairman and CEO. Terrapin plans to use TRAP, its proprietary chemoinformatics technology, and its diverse small-molecule compound library to identify compounds that exhibit a high affinity for Pharmagene's targets. When promising compounds are identified, the companies intend to expand the collaboration into a joint research and development program to deliver clinical candidates.

Pharmagene is a drug discovery company whose proprietary databases link discoveries in gene and protein expression and pharmacology with human pathology. Terrapin, launched in 1987, is a privately held pharmaceutical discovery company.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.